Navigation Links
Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:8/27/2008

SAN FRANCISCO, Aug. 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), today announced that Peter Strumph, Chief Executive Officer of Nile, will present at the NewsMakers in the Biotech Industry conference on Thursday, September 4, at 1:30 p.m. EDT at the Millennium Broadway Hotel in New York City. Mr. Strumph will provide a company overview and update on the status of Nile's current clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Nile's website at http://www.nilethera.com. The webcast will be archived for 90 days.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

415-875-7880

info@nilethera.com

This press release contains forward-looking statements within the meani
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
2. Cell Therapeutics, Inc. Announces Reverse Stock Split
3. Pixel Bridge Works With Anika Therapeutics to Launch New Website
4. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
5. Arno Therapeutics Announces Second Quarter 2008 Financial Results
6. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
7. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... May 20, 2013 With bed bugs' presence ... that although bed bugs need to be eliminated, one must ... compromise a person's health. And so to help bed bug ... get rid of bed bugs without using harmful ... bug spray it called Bed Bug Bully. , According to ...
(Date:5/20/2013)... CHAPEL HILL, N.C. , May 20, 2013 ... pharmaceutical company focused on developing differentiated antibiotics to ... bacterial infections, today announced that it presented data ... 2013) in Philadelphia demonstrating ... versus levofloxacin in Cempra,s prior Phase 2 clinical ...
(Date:5/20/2013)... 2013 Rhythm announced today the results of ... company,s novel ghrelin agonist for the treatment of diabetic ... that RM-131 significantly accelerates early gastric emptying and reduces ... with diabetic gastroparesis. The findings were presented at the ... and recently published in Clinical Gastroenterology ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... FRANKFURT, Germany and LAUSANNE, Switzerland ... IMIDIA ("Innovative Medicines Initiative for,Diabetes"), a public private consortium ... launch of a project focusing on,pancreatic islet cell function ... to develop biomarkers and tools to pave the way,for ...
... CAMBRIDGE, England , June 14, 2010 Executives ... under,which O2h will provide Senexis with chemistry services to support a patent,filing ... disease modifying treatments for Alzheimer,s Disease. , ... Dr. Mark Treherne , CEO ...
... , NEW YORK and JERUSALEM , ... a privately held biopharma company, announced that it has ... safety and pharmacokinetics (PK) of its proprietary product Octreolin, ... administered orally. Octreolin demonstrated a PK profile similar ...
Cached Biology Technology:Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 2Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 3Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes 4O2h Continues to Support Senexis to Support Patent Filing Senexis Limited 2Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 2Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 3Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 4Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 5Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 6Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 7Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 8Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study 9
(Date:5/16/2013)... African-American adults living closer to a fast food restaurant ... who lived further away from fast food, according to ... Center, and this association was particularly strong among those ... published online in the American Journal of Public ... to a fast food restaurant, and among lower-income African-Americans, ...
(Date:5/16/2013)... a gene involved in neurodegenerative disease also plays a ... clock. , In a study of the common ... keeps the clock responsible for sleeping and waking on ... the fruit fly,s sleep-wake cycle is disturbed, making waking ... , The discovery is particularly interesting because mutations ...
(Date:5/16/2013)... the cellular layer lining the body,s blood vessels, ... nanometers in thickness, this super-tenuous structure routinely withstands ... to create a unique and highly dynamic barrier ... from the body,s circulatory system. , It,s also ... be physically breached to enable immune cells ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Gene involved in neurodegeneration keeps clock running 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... Alexandria, Va. The American Association for Dental Research ... AADR Neal W. Chilton Fellowship in Clinical Research recipient. ... & Exhibition in Washington, DC, March 3, 2010. ... associate director of the Delta Dental of Kentucky Clinical ...
... Foundation has awarded a $630,100 project support grant ... support the initial implementation this year of a ... for primary care providers, technical staff and health ... Building Blocks (HIBBs), a program developed by AMIA ...
... Lori Marino will speak on the anatomical basis of dolphin ... conference (AAAS) in San Diego, on Sunday, Feb. 21 at ... than our own and second in mass to the human ... leading expert in the neuroanatomy of dolphins and whales, Marino ...
Cached Biology News:Rockefeller Foundation supports expansion, training of e-health work force in developing world 2Rockefeller Foundation supports expansion, training of e-health work force in developing world 3
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Glutathione Agarose Beads 10 ml...
...
Biology Products: